Specialized to manufacture oral solid dosage forms, Alcami’s Wilmington, North Carolina site supports preclinical production through commercial launch and supply. Our cGMP manufacturing technologies are arranged in flexible suites to support advanced and complex projects.
Due to counterfeiting, adulteration, theft, and diversion, governments and regulatory agencies have developed regulations to enhance patient safety and supply chain security. On November 27, 2013, the Drug Supply Chain Security Act (DSCSA) made effective several additional requirements that impact labeling and data management for commercially distributed prescription human drug product in the United States.
Whether you are looking for an all-inclusive integrated offering or an individualized development or manufacturing service, Alcami has the solution to the complex needs of your product.
The increasing trend of highly potent active pharmaceutical ingredients (HPAPIs) being used in new drug development candidates has created a tremendous demand for high containment development and production capabilities.
Balancing HPAPI Control with the Chemistry and Efficiency Needs of a CDMO
Extractables & Leachables 101: The Past, Present, and Future
Submitting Samples through Alcami OnDemand™
eBook: Elemental Impurities
Editorial: An Interview with Alcami
Editorial: Oral Solids Endure & Evolve
Editorial: HPAPIs - A CDMO View
Editorial: Fuelling Pharma's Innovation Engines
Alcami Kickstarts Biologics Enterprise to Advance Treatments for Complex Medical Conditions
Connect Faster: Introducing Alcami RightNow™
World Orphan Drug Congress - April 10-212019 Life Science Innovation Northwest - April 24-25ASGCT - April 29 - May 2CPhI North America - April 30 - May 2
